Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$167 Mln
Revenue (TTM)
$60 Mln
Net Profit (TTM)
$0 Mln
ROE
-1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.2
Industry P/E
65.05
EV/EBITDA
-1
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
11,792,200
CFO
$-61.75 Mln
EBITDA
$-72.07 Mln
Net Profit
$-91.58 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
LENSAR (LNSR)
| 57.8 | 4.5 | 34.4 | 240.0 | 26.1 | -- | -- |
|
BSE Sensex
| 5.2 | 7.3 | 8.4 | 12.8 | 16.0 | 21.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
LENSAR (LNSR)
| 152.8 | 18.6 | -50.6 | -17.4 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
LENSAR (LNSR)
|
14.1 | 167.2 | 59.6 | -48.0 | -9.0 | -347.5 | -- | 2.2 |
| 13.4 | 8,749.6 | 6,685.2 | 715.6 | 16.4 | 12.3 | 12.3 | 1.4 | |
| 250.1 | 7,012.7 | 2,541.1 | -2,228.1 | -106.3 | -31.5 | -- | 1.0 | |
| 248.7 | 6,573.3 | 2,541.1 | -2,228.1 | -106.3 | -31.5 | -- | 1.0 | |
| 61.3 | 8,292.0 | 2,510.8 | 185.6 | 8.8 | 4.5 | 45.7 | 1.9 | |
| 72.1 | 8,577.6 | 12,669.0 | 407.0 | 4.0 | 11.8 | 22 | 2.4 | |
| 155.6 | 8,303.7 | 1,973.6 | -494.5 | -15.3 | -41 | -- | 9.3 | |
| 280.7 | 10,662.0 | 1,240.1 | 42.2 | 4.1 | 3.6 | 257.3 | 8.8 | |
| 117.7 | 14,455.8 | 3,357.5 | 396.9 | 16.3 | 5.4 | 41.5 | 2.6 | |
| 126.5 | 7,193.7 | 645.7 | -25.4 | 6.8 | -1.3 | -- | 3.7 |
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System.... The company offers LENSAR Laser System which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida. Address: 2800 Discovery Drive, Orlando, FL, United States, 32826 Read more
President, CEO & Director
Mr. Nicholas T. Curtis
President, CEO & Director
Mr. Nicholas T. Curtis
Headquarters
Orlando, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of LENSAR Inc (LNSR) stood at $ 108 Mln as on 31-Mar-25
The share price of LENSAR Inc (LNSR) is $14.11 (NASDAQ) as of 16-May-2025 16:00 EDT. LENSAR Inc (LNSR) has given a return of 26.08% in the last 3 years.
LENSAR Inc (LNSR) has a market capitalisation of $ 167 Mln as on 15-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of LENSAR Inc (LNSR) is 2.17 times as on 15-May-2025, a 40% discount to its peers’ median range of 3.64 times.
Since, TTM earnings of LENSAR Inc (LNSR) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the LENSAR Inc (LNSR) and enter the required number of quantities and click on buy to purchase the shares of LENSAR Inc (LNSR).
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System. The company offers LENSAR Laser System which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida. Address: 2800 Discovery Drive, Orlando, FL, United States, 32826
The CEO & director of Mr. Nicholas T. Curtis. is LENSAR Inc (LNSR), and CFO & Sr. VP is Mr. Nicholas T. Curtis.
There is no promoter pledging in LENSAR Inc (LNSR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,119
|
|
|
1,073
|
|
|
876
|
|
|
858
|
|
|
830
|
|
|
787
|
|
|
719
|
|
|
687
|
|
|
687
|
| LENSAR Inc. (LNSR) | Ratios |
|---|---|
|
Return on equity(%)
|
-347.46
|
|
Operating margin(%)
|
-9.01
|
|
Net Margin(%)
|
-80.4
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of LENSAR Inc (LNSR) was $0 Mln.
$-0.01
(
